E
Eisbach Bio
Innovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes
About Eisbach Bio
Eisbach Bio is a biotech startup that operates in the field of precision medicine, specifically in the development of innovative cancer therapies. The company's primary focus is on creating drugs that target the molecular machines that drive tumor evolution. These machines are responsible for the reorganization of the tumor genome, a process that is vital to the growth and survival of cancer cells. By disrupting these machines, Eisbach Bio aims to halt tumor growth and introduce new treatment options for cancer patients.
Read full description
The company's business model revolves around the discovery and development of allosteric drugs, a new class of drugs that work by binding to a protein in a cell and changing its shape, thereby altering its function. Eisbach Bio's drugs are designed to target specific molecular machines involved in genome reorganization, such as nucleosome remodeling enzymes and DNA-dependent nuclear helicases. These targets are critical to the development of a majority of human cancers, making Eisbach Bio's drugs potentially effective against a wide range of cancer types.
Eisbach Bio's revenue is likely to come from the sale of its drugs once they have been approved for use. Given the high prevalence of cancer and the ongoing need for new treatments, the market potential for Eisbach Bio's drugs is significant.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Planegg, Germany
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 83.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Precision Medicine, Spinout, Headstart (EIT Health), Headstart 2019 (EIT Health), Biotech and Pharma, EIT Health, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2025 | $0 | — | Kalczynski Consult | — |
| EARLY VC✓Equity / VC | Mar 2024 | $4.6M | $37M | Cancer Focus Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Eisbach Bio is 320 monthly website visits, down 56.2% over the last three months. Eisbach Bio's team grew 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Bavarian Ministry of Economic Affairs, Regional Development and Energy
Cancer Focus Fund- KCKalczynski Consult
Other known investors4 additional known investors
EIT Health
Ludwig Maximilian University of Munich- JMJoao Monteiro
Pinto Ventures AG
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eisbach Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eisbach Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.